← All trials
NCT02421770
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2014
- Primary completion
- Jan 31, 2015
- Completion date
- Jul 31, 2015
- First posted
- Apr 21, 2015
- Last posted
- Dec 2, 2015
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad de MurciaLead sponsor
- Universidad de MurciaOverall official - principal investigator
- Universidad de MurciaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.